James F. Howard, Jr., MD, FAAN, University of North Carolina School of Medicine, Chapel Hill, NC, presents the rationale and design for the PREVAIL trial (NCT05556096), a Phase III study of ALXN1720 in adults with anti-acetylcholine receptor antibody-positive (AChR Ab+) generalized myasthenia gravis (gMG). ALXN1720 is a novel bispecific antibody that binds to complement component 5 (C5) and albumin, which increases its half-life, facilitating weekly dosing. Around 200 patients will be randomized to receive ALXN1720 or placebo. PREVAIL consists of a 4-week screening period, a 26-week randomized controlled treatment phase, and a 96-week open-label extension period. The trial is currently active and recruiting patients in multiple countries. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
